Streetbeat News

Regulatory

ALLR

Allarity Therapeutics, Inc. (ALLR) announced positive outcomes from its Phase 2 trial of Stenoparib, showing clear clinical benefits. The company also reported improvements in its financial position, with a cash balance of $14M and equity balances of $15M. Additionally, Allarity is on track to regain compliance with Nasdaq listing requirements, has no variable priced securities outstanding, and has nearly eliminated warrant overhang. The company has withdrawn its Form S-1, signaling a strategic shift or achievement of required funding through other means.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:09 pm

CRIS

Curis, Inc. announced an update on its TakeAim Leukemia study, expanding the AML dataset from 5 to 30 patients. The update will be presented at the ASCO and EHA conferences, including data for 25 new patients treated with emavusertib.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:02 pm

BEAM

Beam Therapeutics Inc. announced it will present data on the manufacturing process for BEAM-101 at the EHA 2024 Hybrid Congress. The data highlights a robust, closed, and automated process used in the BEACON Phase 1/2 clinical trial for sickle cell disease treatment.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:00 pm

MAG

MAG Silver Corp. has filed a preliminary short form base shelf prospectus in Canada and plans to file a corresponding registration statement in the U.S. This will allow the company to offer up to $250M of various securities over a 25-month period once the final prospectus is effective.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:44 pm

BTCUSD

ETHUSD

A report by 10x Research suggests this week's inflation data could cause volatility for Bitcoin, with a potential +/-6% price move. The report advises buying Bitcoin if bullish and shorting Ethereum if bearish, ahead of the inflation data release. It also notes Bitcoin's support level around $60,800-$61,400 and the average entry price for Bitcoin ETFs at $57,000. The report predicts a meaningful rally for Bitcoin later in the year, despite immediate headwinds and a potentially pivotal SEC decision on an Ethereum ETF.

Portfolio Pulse from Murtuza Merchant

May 14, 2024 | 7:29 pm

FXI

SPY

TikTok creators have filed a lawsuit to prevent the enforcement of a U.S. law that mandates the platform to be divested or face a ban. This legal action underscores the ongoing tension between TikTok, owned by ByteDance, a Chinese company, and U.S. regulatory authorities concerned about data privacy and national security. The outcome of this lawsuit could have significant implications for TikTok's operations in the U.S. and for U.S.-China relations.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:23 pm

UUUU

President Joe Biden signed a law banning enriched uranium imports from Russia, aiming to cut off Moscow's war funding in Ukraine and boost North American uranium miners. Energy Fuels (UUUU) sees this as a step towards reducing dependency on Russian nuclear fuel. The law also unlocks $2.7 billion for the U.S. domestic conversion and enrichment supply chain, indirectly benefiting domestic miners.

Portfolio Pulse from Matt Whittaker

May 14, 2024 | 7:07 pm

BA

LMT

The Lockheed-Boeing alliance is facing penalties from the U.S. Air Force due to a delay in launch schedules, with specific details on the withheld fees not disclosed. The Air Force has cited a 'schedule slip' as the reason for the penalties.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:04 pm

INO

Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO) with an Overweight rating and a price target of $20, highlighting the company's diversified clinical pipeline and the potential of its lead program INO-3107 for Accelerated Approval by the FDA. INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), could become the first non-surgical treatment for RRP. The FDA marketing application submission for INO-3107 is expected in the second half of 2024. The company's DNA Medicines pipeline also includes early-stage programs for various diseases. The analyst believes the leadership's efficiencies will de-risk the platform technology.

Portfolio Pulse from Vandana Singh

May 14, 2024 | 6:37 pm